Non-high-density lipoprotein cholesterol (non-HDL-cholesterol) in chronic kidney disease: Clinical and functional significance
Abstract. In recent years, increasing attention has been paid to the index non-high-density lipoprotein cholesterol (non-HDL-cholesterol), an elevated level of which is considered as a factor for the progression of atherosclerotic cardiovascular and renal diseases.Murkamilov I.T., Aitbaev K.A., Fomin V.V., urkamilova Zh.A., Mikhin V.P., Raimzhanov Z.R., Khakimov Sh.Sh., Solizhonov Zh.I., Yusupova T.F., Yusupov F.A., Gasanov K.A., Zakirov O.T., Khabibullaev K.K., Ymankulov D.S., Abdibaliev I.A.
The aim: to assess the incidence and clinical and functional manifestations of elevated non-HDL-cholesterol in patients with chronic kidney disease (CKD).
Material and methods. This retrospective analysis included data from 553 patients with CKD aged 18–70 years (mean age 37.7 ± 12.4 years). All subjects underwent clinical laboratory testing, including a blood lipid profile. Non-HDL-cholesterol level was defined as the difference between total cholesterol and high-density lipoprotein cholesterol; non-HDL-cholesterol was considered as elevated if its level was ≥ 3.7 mmol/L.
Results. Elevated non-HDL-cholesterol was detected in 57.3% of patients with CKD (56.3% in male and 59.2% in female individuals). The average non-HDL-cholesterol level was 4.76 mmol/L (4.84 mmol/L in males and 4.59 mmol/L in females). The highest frequency of this index increase was fixed at CKD stages C3B (70.0%), C2 (68.1%), C3A (65.5%) and C1 (58.5%). In males, its high values were more often recorded at stages C1 (16.8%), C2 (13.2%) and C5 (10.2%), and in females – at stages C2 (14.1%), C5 (11.4%) and C1 (10.8%). Median non-HDL-cholesterol values were statistically significantly higher in the early stages of CKD. Reliable correlations were established between the level of non-HDL-cholesterol and systolic blood pressure (r = -0.099), hemoglobin content (r = 0.266), platelet number (r = 0.235), erythrocyte sedimentation rate (r = 0.370), fibrinogen levels (r = 0.613), total protein (r = -0.575), albumin (r = -0.558), creatinine (r = –0.216), estimated glomerular filtration rate (r = 0.236) and daily proteinuria (r = 0.501).
Conclusion. Patients with CKD often have elevated levels of non-HDL-cholesterol, which likely reflects the activity of the pathological process in renal tissue. The identified associations between non-HDL-cholesterol levels and clinical and laboratory parameters confirm the advisability of their assessment as part of routine follow-up to slow the progression of renal failure and reduce the risk of cardiovascular complications.
Keywords
chronic kidney disease
cholesterol
non-high-density lipoprotein cholesterol (non-HDL-cholesterol)
cardiovascular risk
renal failure
prognosis
healthcare
References
1. Драпкина О.М., Кобалава Ж.Д., Шестакова М.В., Бобкова И.Н., Ефремовцева М.А., Виллевальде С.В. с соавт. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Междисциплинарный консенсус. Кардиоваскулярная терапия и профилактика. 2025;24(6):113–151. (Drapkina OM, Kobalava ZhD, Shestakova MV, Bobkova IN, Efremovtseva MA, Villevalde SV et al. Cardiovascular risk and chronic kidney disease: Strategies for cardiac and renal protection. Interdisciplinary consensus. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2025;24(6):113–151 (In Russ.)).
EDN: MIARUF. https://orcid.org/10.15829/1728-8800-2025-4466
2. Драпкина О.М., Мазуров В.И., Мартынов А.И., Насонов Е.Л., Сайганов С.А., Лила А.М. с соавт. Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике. Кардиоваскулярная терапия и профилактика. 2024;23(1):89–104. (Drapkina OM, Mazurov VI, Martynov AI, Nasonov EL, Saiganov SA, Lila AM. et al. Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2024;23(1):89–104 (In Russ.)).
EDN: WXKMIG. https://orcid.org/10.15829/1728-8800-2024-3737
3. Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3–15.
PMID: 31399958. https://orcid.org/10.1007/978-981-13-8871-2_1
4. Коновалова Д.Ю., Лебедев П.А., Жарков М.Н. Значимость параметра аутофлуоресценции кожи в стратификации риска летальности и сердечно-сосудистых событий у пациентов, получающих программный гемодиализ. Терапия.2025;11(1):125–133. (Konovalova DYu, Lebedev PA, Zharkov MN. The importance of skin autofluorescence parameter in stratification of risk of mortality and cardiovascular events in patients receiving programmed hemodialysis. Terapiya = Therapy. 2025;11(1):125–133 (In Russ.)).
EDN: VLSJSU. https://orcid.org/10.18565/therapy.2025.1.125-133
5. Шилов Е.М., Шилова М.М., Румянцева Е.И., Батюшин М.М., Бевзенко А.Ю., Бельских А.Н. с соавт. Нефрологическая служба Российской Федерации 2023: часть I. Заместительная почечная терапия. Клиническая нефрология. 2024;16(1):5–14. (Shilov EM, Shilova MM, Rumyantseva EI, Batyushin MM, Bevzenko AYu, Belskikh AN et al. Nephrological service of the Russian Federation 2023: Part I. Renal Replacement Therapy. Klinicheskaya nefrologiya = Clinical Nephrology. 2024;16(1):5–14 (In Russ.)).
EDN: DAZGYH. https://orcid.org/10.18565/nephrology.2024.1.5-14
6. Chen S, Chen L, Jiang H. Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: A prospective cohort CKD-ROUTE study. Ren Fail. 2022;44(1):1309–18.
PMID: 35938702. PMCID: PMC9361770. https://orcid.org/10.1080/0886022X.2022.2106872
7. Marx-Schutt K, Cherney DZI, Jankowski J, Matsushita K, Nardone M, Marx N. Cardiovascular disease in chronic kidney disease. Eur Heart J. 2025;46(23):2148–60.
PMID: 40196891. PMCID: PMC12167664. https://orcid.org/10.1093/eurheartj/ehaf167
8. Yu B, Li M, Yu Z, Zheng T, Feng X, Gao A et al. The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) as a predictor of all-cause and cardiovascular mortality in US adults with diabetes or prediabetes: NHANES 1999–2018. BMC Med. 2024;22(1):317.
PMID: 39113030. PMCID: PMC11304565. https://orcid.org/10.1186/s12916-024-03536-3
9. Бойцов С.А., Вавилова Т.В., Гуревич В.С., Драпкина О.М., Дроздова Л.Ю., Ежов М.В. с соавт. Место холестерина, не связанного с липопротеинами высокой плотности, и триглицеридов в оценке сердечно-сосудистого риска: резолюция Совета экспертов. Профилактическая медицина. 2025;28(4):7–15. (Boytsov SA, Vavilova TV, Gurevich VS, Drapkina OM, Drozdova LYu, Yezhov MV et al. The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine. 2025;28(4):7–15 (In Russ.)).
EDN: MZSVNE. https://orcid.org/10.17116/profmed2025280417
10. Смирнов А.В., Ватазин А.В., Добронравов В.А., Бобкова И.Н., Ветчинникова О.Н., Волгина Г.В. с соавт. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10–84. (Smirnov AV, Vatazin AV, Dobronravov VA, Bobkova IN, Vetchinnikova ON, Volgina GV et al. Clinical recommendations. Chronic kidney disease (CKD). Nefrologiya = Nephrology (Saint-Petersburg). 2021;25(5):10–84 (In Russ.)).
EDN: GHHTEG. https://orcid.org/10.36485/1561-6274-2021-25-5-10-84
11. Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. с соавт. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):250–297. Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023;28(5):250–297 (In Russ.)).
EDN: YVZOWJ. https://orcid.org/10.15829/1560-4071-2023-5471
12. Канорский С.Г., Мамедов М.Н. Коррекция гипертриглицеридемии и пути улучшения прогноза пациентов. Международный журнал сердца и сосудистых заболеваний. 2024;12(42):39–48. (Kanorskiy SG, Mamedov MN. Correction of hypertriglyceridemia and ways to improve the prognosis of patients. Mezhdunarodnyy zhurnal serdtsa i sosudistykh zabolevaniy = International Journal of Heart and Vascular Diseases. 2024;12(42):39–48 (In Russ.)).
EDN: JNSHUD. https://orcid.org/10.24412/2311-1623 2024-42-39-48
13. Cao Y, Yan L, Guo N, Yu N, Wang Y, Cao X et al. Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2019;147:1–8.
PMID: 30448450. https://orcid.org/10.1016/j.diabres.2018.11.002
14. Cui Y, Choi M. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and angina pectoris in US adults: A cross-sectional retrospective study based on NHANES 2009–2018. Lipids Health Dis. 2024;23(1):347.
PMID: 39462375. PMCID: PMC11514896. https://orcid.org/10.1186/s12944-024-02343-2
15. Shoar S, Ikram W, Shah AA, Farooq N, Gouni S, Khavandi S et al. Non-high-density lipoprotein (non-HDL) cholesterol in adolescence as a predictor of atherosclerotic cardiovascular diseases in adulthood. Rev Cardiovasc Med. 2021;22(2):295–99.
PMID: 34258898. https://orcid.org/10.31083/j.rcm2202037
16. Сергиенко И.В. Российские клинические рекомендации по нарушению липидного обмена 2024 г. Что нового? РМЖ. 2023;(4):12–17. (Sergiyenko IV. Russian clinical guidelines on lipid metabolism disorders 2024. What’s new? Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2023;(4):12–17 (In Russ.)). EDN: WQBIOE.
17. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28(8):1916–21.
PMID: 16043732. https://orcid.org/10.2337/DIACARE.28.8.1916
18. Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol. 2009;55(1):42–44.
PMID: 20117362. https://orcid.org/10.1016/J.JACC.2009.07.056
19. Полякова О.А., Черемушкин С.В., Остроумова О.Д. Коррекция гипертриглицеридемии как одна из основ снижения остаточного сердечно-сосудистого риска: фокус на фенофибрат. Кардиология: новости, мнения, обучение. 2023;11(1):42–50. (Polyakova OA, Cheremushkin SV, Ostroumova OD. Correction of hypertriglyceridemia as a basis for reducing residual cardiovascular risk: Focus on fenofibrate. Kardiologiya: novosti, mneniya, obuchenie = Cardiology: News, Opinions, Training.2023;11(1):42–50 (In Russ.)).
EDN: HSMHHC. https://orcid.org/10.33029/2309-1908-2023-11-1-42-50
20. Theofilis P, Vlachakis PK, Karakasis P, Kalaitzidis RG. Managing dyslipidemia in chronic kidney disease: Implications for cardiovascular and renal risk. Curr Atheroscler Rep. 2025;27(1):41.
PMID: 40117057. https://orcid.org/10.1007/s11883-025-01290-2
21. Муркамилов И.Т., Сабиров И.С., Муркамилова Ж.А., Фомин В.В., Астанин П.А., Юсупов Ф.А. Структурно-функциональное состояние левых отделов сердца при хронической болезни почек С4–С5 стадий. Нефрология. 2022;26(4):31–39. (Murkamilov IT, Sabirov IS, Murkamilova ZA, Fomin VV, Astanin PA, Yusupov FA. Structural and functional state of the left parts of the heart in chronic kidney disease stage C4–C5. Nefrologiya = Nephrology (Saint-Petersburg). 2022;26(4):31–39 (In Russ.)).
EDN: ATAQGU. https://orcid.org/10.36485/1561-6274-2022-26-4-31-39
22. Кутырина И.М., Руденко Т.Е., Савельева С.А., Швецов М.Ю., Васильева М.П. Факторы риска поражения сердечно-сосудистой системы при хронической болезни почек. Терапевтический архив. 2013;85(9):69–76. (Kutyrina IM, Rudenko TE, Savelieva SA, Shvetsov MIu, Vasilieva MP. Risk factors for cardiovascular system damage in chronic kidney disease. Terapevticheskiy arkhiv = Therapeutic Archive. 2013;85(9):69–76 (In Russ.)). EDN: RTKQVL.
23. Brunner FJ, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S et al; Multinational Cardiovascular Risk Consortium. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: Results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019;394(10215):2173–83.
PMID: 31810609. PMCID: PMC6913519. https://orcid.org/10.1016/S0140-6736(19)32519-X
24. Hansen MK, Mortensen MB, Warnakula Olesen KK, Thrane PG, Maeng M. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: A cohort study. Lancet Reg Health Eur. 2023;36:100774.
PMID: 38019978. PMCID: PMC10652132. https://orcid.org/10.1016/j.lanepe.2023.100774
25. Каширина А.П., Симонова Г.И. Холестерин, не связанный с липопротеинами высокой плотности, и кардиометаболические заболевания. Атеросклероз. 2024;20(2):183–194. (Kashirina AP, Simonova GI. Non-high-density lipoproteins cholesterol and cardiometabolic diseases. Ateroskleroz = Atherosclerosis. 2024;20(2):183–194 (In Russ.)).
EDN: KKKDMG. https://orcid.org/10.52727/2078-256X-2024-20-2-183-194
26. Шальнова С.А., Метельская В.А., Куценко В.А., Яровая Е.Б., Капустина А.В., Муромцева Г.А. с соавт. Холестерин, не входящий в состав липопротеинов высокой плотности: современный ориентир оценки нарушений липидного обмена. Рациональная фармакотерапия в кардиологии. 2022;18(4):366–375. (Shalnova SA, Metelskaya VA, Kutsenko VA, Yarovaya EB, Kapustina AV, Muromtseva GA et al. Non-high density lipoprotein cholesterol: A modern benchmark for assessing lipid metabolism disorders. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2022;18(4):366–375 (In Russ.)).
EDN: PSCNVF. https://orcid.org/10.20996/1819-6446-2022-07-01
About the Authors
Ilkhom T. Murkamilov, MD, Dr. Sci. (Medicine), corresponding member of the Russian Academy of Natural History, associate professor of the Department of faculty therapy named after M.E. Volsky – M.M. Mirrakhimov, I.K. Akhunbaev Kyrgyz State Medical Academy. Address: 720020, Kyrgyzstan, Bishkek, 92 Akhunbaeva St.E-mail: murkamilov.i@mail.ru
ORCID: https://orcid.org/0000-0001-8513-9279
Kubanych A. Aitbaev, MD, professor, I.K. Akhunbaev Kyrgyz State Medical Academy. Address: 720020, Kyrgyzstan, Bishkek, 92 Akhunbaeva St.
E-mail: kaitbaev@yahoo.com
ORCID: https://orcid.org/0000-0003-4973-039X
Viktor V. Fomin, MD, Dr.Sci. (Medicine), professor, academician of RAS, rector of the Russian Medical Academy of Continuous Professional Education. Address: 125993, Moscow, 2/1 bldg. 1 Barrikadnaya St.
E-mail: fomin_vic@mail.ru
ORCID: https://orcid.org/0000-0002-2682-4417
Zhamila A. Murkamilova, MD, physician, research doctor of Family Medicine Center No. 7. Address: 720040, Kyrgyzstan, Bishkek, 3 Togolok Moldo St.
E-mail: murkamilovazh.t@mail.ru
ORCID: https://orcid.org/0000-0002-7653-0433
Vadim P. Mikhin, MD, Dr. Sci. (Medicine), professor, head of the Department of internal medicine No. 2, Kursk State Medical University of the Ministry of Healthcare of Russia. Address: 305041, Kursk, 3 K. Marksa St.
ORCID: https://orcid.org/0000-0002-5398-9727
Zafarbek R. Raimzhanov, MD, neurologist at 29th Department of neurology, N.N. Burdenko Main Military Clinical Hospital of the Ministry of Defence of the Russian Federation. Address: 105094, Moscow, 3 Gospitalnaya Sq.
E-mail: rzrmam@mail.ru
ORCID: https://orcid.org/0000-0001-5746-6731
Shavkat S. Khakimov, MD, resuscitation specialist, researcher, Clinical Hospital under the Administrative Department of the President of the Kyrgyz Republic. Address: 720040, Kyrgyzstan, Bishkek, 110 Kievskaya St.
E-mail: hakimovshaki13@gmail.com
ORCID: https://orcid.org/0009-0004-0437-0188
Zhaloliddin I. Solizhonov, resident of Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation. Address: 100058, Uzbekistan, Tashkent, 3, 6 proezd Yangishakhar St.
E-mail: solijonov_jaloliddin@icloud.com
ORCID: https://orcid.org/0009-0003-0078-0609
Tursunoy F. Yusupova, resident of the Department of neurology, neurosurgery, and psychiatry of the Faculty of general medicine, Osh State University. Address: 723500, Kyrgyzstan, Osh, 331 Lenina St.
E-mail: furcat_y@mail.ru
ORCID: https://orcid.org/0000-0002-8502-2203
Furkat A. Yusupov, MD, Dr. Sci. (Medicine), professor, head of the Department of neurology, neurosurgery, and psychiatry of the Faculty of general medicine, Osh State University. Address: 723500, Kyrgyzstan, Osh, 331 Lenina St.
E-mail: yusupov_ts_f@mail.ru
ORCID: https://orcid.org/0000-0003-0632-6653
Kamranbey A. Gasanov, clinical resident of the Department of neurology and clinical genetics, I.K. Akhunbaev Kyrgyz State Medical Academy. Address: 720020, Kyrgyzstan, Bishkek, 92 Akhunbaeva St.
E-mail: gassanov_k@mail.ru
Omurbek T. Zakirov, MD, assistant professor of the Department of neurology, neurosurgery, and psychiatry of the Faculty of general medicine, Osh State University. Address: 723500, Kyrgyzstan, Osh, 331 Lenina St.
E-mail: omurbekzakirov@gmail.com
ORCID: https://orcid.org/0009-0002-8732-7374
Komil K. Khabibullaev, MD, research doctor, I.K. Akhunbaev Kyrgyz State Medical Academy. Address: 720020, Kyrgyzstan, Bishkek, 92 Akhunbaeva St.
E-mail: khabibullaevkomil2001@gmail.com
ORCID: https://orcid.org/0009-0004-5508-8019
Daniyar S. Ymankulov, MD, research doctor, I.K. Akhunbaev Kyrgyz State Medical Academy. Address: 720020, Kyrgyzstan, Bishkek, 92 Akhunbaeva St.
E-mail: ymankulov9595@mail.ru
ORCID: https://orcid.org/0009-0000-4975-1196
Ibadilla A. Abdibaliev, MD, research doctor, I.K. Akhunbaev Kyrgyz State Medical Academy. Address: 720020, Kyrgyzstan, Bishkek, 92 Akhunbaeva St.
E-mail: ibadillaabdibaliev307@gmail.com
ORCID: https://orcid.org/0009-0002-0921-0410
Similar Articles
